# First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

> **NCT07756281** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Synnovation Therapeutics, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Acinar Carcinoma

## Interventions

- **DRUG:** SNV1521
- **DRUG:** daraxonrasib

## Key facts

- **NCT ID:** NCT07756281
- **Lead sponsor:** Synnovation Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07756281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07756281, "First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07756281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*